Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Ricci

Showing results (301-310 of 595) with videos related to

Pageof 60
Sort By:
Discover Oncology|February 24, 2022
Involvement of transcribed lncRNA uc.291 and SWI/SNF complex in cutaneous squamous cell carcinomaM Mancini, A Cappello, R Pecorari, et al.
International Journal of Immunopathology and Pharmacology|October 14, 2009
Angiogenic potential of human dental pulp stromal (stem) cellsC Marchionni, L Bonsi, F Alviano, et al.
Investigational New Drugs|April 7, 2019
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinomaC Even, U Lassen, J Merchan, et al.
International Journal of Clinical Practice|November 20, 2013
Insomnia as a predictor of high-lethality suicide attemptsM Pompili, M Innamorati, A Forte, et al.
The Journal of Vascular Access|April 6, 2006
Incidence of sepsis in central venous catheter-bearing patients with hematologic malignancies: preliminary resultsA Nosari, M Nichelatti, A De Gasperi, et al.
British Journal of Cancer|November 4, 2021
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenograftsF Guffanti, M F Alvisi, A Anastasia, et al.
Leukemia|May 23, 2012
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemiaC Simioni, L M Neri, G Tabellini, et al.
British Journal of Cancer|February 16, 2023
Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenograftsF Guffanti, M F Alvisi, A Anastasia, et al.
Leukemia|December 7, 2013
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemiaA Lonetti, I L Antunes, F Chiarini, et al.
Leukemia|March 5, 2010
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanismsA M Martelli, V Papa, P L Tazzari, et al.
Pageof 60

Showing results (301-310 of 595) with videos related to

Sort By:
Pageof 60
Discover Oncology|February 24, 2022
Involvement of transcribed lncRNA uc.291 and SWI/SNF complex in cutaneous squamous cell carcinomaM Mancini, A Cappello, R Pecorari, et al.
International Journal of Immunopathology and Pharmacology|October 14, 2009
Angiogenic potential of human dental pulp stromal (stem) cellsC Marchionni, L Bonsi, F Alviano, et al.
Investigational New Drugs|April 7, 2019
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinomaC Even, U Lassen, J Merchan, et al.
International Journal of Clinical Practice|November 20, 2013
Insomnia as a predictor of high-lethality suicide attemptsM Pompili, M Innamorati, A Forte, et al.
The Journal of Vascular Access|April 6, 2006
Incidence of sepsis in central venous catheter-bearing patients with hematologic malignancies: preliminary resultsA Nosari, M Nichelatti, A De Gasperi, et al.
British Journal of Cancer|November 4, 2021
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenograftsF Guffanti, M F Alvisi, A Anastasia, et al.
Leukemia|May 23, 2012
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemiaC Simioni, L M Neri, G Tabellini, et al.
British Journal of Cancer|February 16, 2023
Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenograftsF Guffanti, M F Alvisi, A Anastasia, et al.
Leukemia|December 7, 2013
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemiaA Lonetti, I L Antunes, F Chiarini, et al.
Leukemia|March 5, 2010
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanismsA M Martelli, V Papa, P L Tazzari, et al.
Pageof 60